Psilocybin and Alzheimer’s disease: what early research shows, and what it doesn’t

Headlines about psilocybin and Alzheimer’s tend to run ahead of the science. The idea is easy to see: psilocybin seems to change how brain cells connect in animals, and dementia is a disease of lost connections. But a plausible idea is not a result. A 2026 review of the field found that no clinical trials of psychedelics in people with dementia had been published (Int J Neuropsychopharmacol abstract, 2026).

This page separates what researchers think might happen from what has actually been measured, and in whom. It does not say what anyone should do, and it covers supervised research only.

Can psilocybin treat or slow Alzheimer’s?

Nothing published shows that it can. The 2026 review put it plainly: clinical evidence for serotonergic psychedelics in neurocognitive disorders “remains extremely limited”, and the proposed mechanisms “lack confirmation in adequately powered clinical studies” (Int J Neuropsychopharmacol abstract, 2026).

Canada’s public health agency says there is currently no cure for dementia, though some treatments may ease symptoms for some people (Public Health Agency of Canada). Psilocybin is not one of those treatments. Health Canada says there are no approved therapeutic products containing psilocybin in Canada or elsewhere (Health Canada).

The research that does exist mostly asks narrower questions: can older adults with mild memory problems be given psilocybin safely in a hospital setting, does it help depression in people with early Alzheimer’s, and does it change brain measures linked to plasticity. None of those questions, even if answered yes, would show that the disease itself slows down.

Why are researchers interested? Three hypotheses

Reviews describe three main lines of reasoning. Each is a hypothesis, built mostly from animal studies and from research on depression in younger adults.

• Plasticity. Psilocin, the compound psilocybin turns into in the body, acts on the serotonin 2A receptor, and reviews link that to increased neural plasticity (Zheng et al., 2024). A Toronto team notes that memory decline has been associated with lower density of this receptor, and that animal studies suggest psilocybin may promote new synapses in learning and memory areas (Bukovsky et al., 2025). For what “rewiring” does and doesn’t mean, see does psilocybin rewire the brain?.
• Inflammation. Chronic brain inflammation is thought to play a role in both Alzheimer’s and depression. Reviews propose that psychedelics may dampen inflammatory signalling (Int J Neuropsychopharmacol abstract, 2026; Zheng et al., 2024).
• Mood. Depression is an established risk factor for later dementia, and depression late in life may be an early sign of it. One review argues that psilocybin’s effects on new nerve cells in the hippocampus and on microglia, the brain’s immune cells, could matter for both conditions, while describing this as a potential role, not a demonstrated one (Haniff et al., 2024). For the depression trials themselves, see psilocybin for depression: what the trials found.

What human studies exist?

We found no completed, published trial of psilocybin in people with dementia. The closest human data are below. They are small, and the designs differ, so the rows cannot be compared with each other. Dose amounts are left out on purpose.

A Toronto study in mild cognitive impairment

The only placebo-controlled study in this area we found is Canadian. At the Centre for Addiction and Mental Health (CAMH) in Toronto, researchers set out to see whether psilocybin changes synaptic density, measured with a PET scan, in people with amnestic mild cognitive impairment, a stage often considered a precursor to Alzheimer’s. Participants aged 60 to 75 were randomized to psilocybin or placebo, with cognitive testing up to 12 weeks afterwards (ClinicalTrials.gov NCT06041152).

A 2025 conference abstract reported pilot data on two participants with MCI and three healthy controls. All completed the procedures; there were no serious or unexpected adverse events, and expected effects such as dizziness (4 people) and altered perception (3) resolved. The authors concluded that psilocybin can be feasibly studied in older adults in a supervised medical setting (Bukovsky et al., 2025). The registry lists the trial as completed in February 2026 with 10 participants and no results posted (ClinicalTrials.gov NCT06041152).

The Johns Hopkins pilot on depression in early Alzheimer’s

Johns Hopkins registered an open-label pilot in 2019 to test whether psilocybin, given under supportive conditions, is safe and effective for depression in people with MCI or early Alzheimer’s. It started in March 2021, plans about 20 participants, and measures change on the Cornell Scale for Depression in Dementia. The record, updated in September 2026, still lists it as recruiting, with primary completion estimated for June 2027 and no results posted (ClinicalTrials.gov NCT04123314).

A related signal from Parkinson’s disease

The first published data on psilocybin in any neurodegenerative disease came from Parkinson’s, not Alzheimer’s. In an open-label pilot, 12 people with mild to moderate Parkinson’s and depression or anxiety received psilocybin with psychotherapy. There were no serious adverse events and no worsening of Parkinson’s symptoms; the most frequent side effects were anxiety, nausea and increased blood pressure. Mood scores fell, and some cognitive test scores improved, up to one to three months later. The authors note that safety concerns had kept people with neurodegenerative disease out of earlier trials, and that the results warrant further study (Bradley et al., 2025). With no control group, practice effects and expectation could explain some of the change.

A single case report in advanced Alzheimer’s

A 2026 case report describes a woman in her eighties with a 10-year history of Alzheimer’s who was given psilocybin-containing mushrooms. The acute phase involved autonomic activation, suspected overheating, heavy sweating and a long deep-sleep-like state. Over the following days and weeks, the authors report returns of speech, continence, walking and social engagement. They state that the findings “do not imply disease reversal” (Lago et al., 2026). A single uncontrolled case cannot show cause, and the rough acute phase is itself a reminder of the risks for a frail older person.

One more human study is often cited: an analysis of 2,503 middle-aged and older Americans found that reported past psychedelic use was linked with better executive function and fewer depressive symptoms, but not with better episodic memory. The survey question grouped marijuana, LSD, MDMA and other drugs together, and the design was cross-sectional, so it cannot show cause or say anything about psilocybin in particular (Fearn and Bhattacharyya, 2024).

What do animal and cell studies show?

• Mice bred to develop Alzheimer’s-like plaques (2025 conference abstract). Mice given psilocybin monthly did better on some memory and mood tests than untreated mice and showed lower markers of brain inflammation and more new neurons. Plaques were not reduced (Madhu et al., 2025).
• Rats with chemically induced Alzheimer’s-like damage (2026). A single psilocybin dose reversed some spatial memory and learning deficits, but did not restore the expected pattern of communication between brain regions. The author calls for replication in larger groups (Shamsedin, 2026).
• Aged mice and human cells (2025). In cell culture, psilocin extended the lifespan of human fibroblasts. In aged female mice treated monthly for 10 months, 80% of the psilocybin group survived compared with 50% of controls (Kato et al., 2025). This is ageing research, not dementia research, and it did not test memory.

The 2026 review noted that surprisingly few studies use animal models of dementia or ageing (Int J Neuropsychopharmacol abstract, 2026). Two of the three studies above are conference abstracts or a single small cohort, so even the animal evidence is thin.

Which trials are registered, and what is their status?

A ClinicalTrials.gov search on 19 October 2026 for psilocybin with Alzheimer’s, dementia or mild cognitive impairment returned three distinct studies. We add two trials in healthy older adults, because safety data from them will matter. A registration shows a study was planned, not that it worked; dates are the sponsors’ own and may change.

The largest, the National Institute on Aging study, asks whether psilocybin adds to the effect of brain training on a plasticity score after four weeks. Its participants stay in the clinic for 24 hours after each session and have a heart test at screening (ClinicalTrials.gov NCT07721467). Even if it succeeds, it measures a plasticity score, not whether dementia progresses more slowly. By the registry’s own dates, results are years away.

What are the open safety questions for older adults?

Older adults have barely been studied. A 2024 systematic review of 36 psychedelic therapy trials with 1,400 participants found only 19 aged 65 or older, under 1.4%. Among the 10 with detailed safety data, there were no serious adverse events; transient anxiety, stomach upset and high blood pressure were reported during sessions (Bouchet et al., 2024). Ten people cannot reveal uncommon risks.

• Blood pressure and heart. A 2026 review reports pooled average rises of about 19 mmHg systolic and 8.7 mmHg diastolic in supervised studies, peaking 60 to 90 minutes after dosing and generally resolving within 4 to 6 hours. It says risk changes with heart disease, interacting medicines, repeated exposure and mushroom products, whose active content can vary by more than tenfold (Szarpak et al., 2026). A pooled analysis of 368 participants at Johns Hopkins, posted as a preprint not yet peer reviewed, found systolic pressure passed 180 mmHg in 3.2% of sessions, briefly; those studies kept excluding people with established cardiovascular disease (Nayak et al., 2026). Heart and blood-pressure problems are common later in life.
• Falls, confusion and frailty. We found no study that measured falls, delirium or confusion after psilocybin in people with dementia. Dizziness was the most common expected effect in the Toronto pilot, and the case report describes overheating and heavy sweating.
• Other medicines. Older adults often take several medicines, and reviews flag drug interactions as a concern (Szarpak et al., 2026). For antidepressants specifically, see magic mushrooms and antidepressants.
• Consent and distress. People with dementia may find an intense, disorienting experience harder to understand or describe. Reviews raise ethical questions about studying psilocybin in Alzheimer’s (Zheng et al., 2024). One cohort study found that acute psychedelic effects were less intense in adults over 60 than in younger adults in group settings, but it did not include people with dementia (Kettner et al., 2024).

What does this evidence not show?

• It does not show that psilocybin slows, stops, prevents or reverses Alzheimer’s or any dementia. No study has tested that in people, and the mouse study that did look found no change in plaques.
• It does not show that psilocybin improves memory in people with dementia. The only human cognitive gains we found came from a 12-person Parkinson’s study without a control group.
• It does not show that psilocybin is safe for people with dementia. The safety data cover a handful of screened people with mild impairment, under medical supervision.
• It does not apply to mushrooms taken at home. Trial participants were screened, monitored and given a measured pharmaceutical product.
• It does not show that brain changes in animals happen in people, or that a change on a scan means a person is better.

Where does Canada stand?

Between April 2022 and March 2023, close to 487,000 people aged 65 and older in Canada were living with diagnosed dementia, and close to 99,000 were newly diagnosed (Public Health Agency of Canada). That scale is one reason any new idea draws attention.

The Health Canada page we confirmed (date modified 20 October 2026) says the production, sale and possession of magic mushrooms are illegal in Canada, that there are no approved therapeutic psilocybin products, and that clinical trials are the most appropriate way to advance research with unapproved drugs such as psilocybin. It lists clinical trials, the Special Access Program and individual exemptions as the legal routes, with a health care practitioner’s support (Health Canada). Canada contributes directly to this research through the CAMH study in Toronto. For broader context, see what the research on psilocybin shows and the short- and long-term effects of magic mushrooms.

What is still unknown?

• Whether psilocybin changes synaptic density or memory in people with mild cognitive impairment. The Toronto trial has finished, but results are not public.
• Whether it eases depression in early Alzheimer’s more than a comparison condition would. The Johns Hopkins pilot has no control group and has not reported.
• How often blood pressure spikes, dizziness, confusion or falls happen in frail older adults and people with dementia.

For now, the accurate summary is that psilocybin and Alzheimer’s is a research question with a hypothesis, some animal data and a handful of very small human studies, not a treatment. For background, see what psilocybin is and what magic mushrooms are. For another area where psilocybin has been studied in seriously ill people, see psilocybin and end-of-life distress.

Shroomverse sells mushroom products. This article is general information about research on psilocybin and dementia. It is not medical, legal or purchasing advice, and it does not recommend any product.